Another gem from @AdityaKhemka5 sir
Opportunity in Health care Sector Cont.. Interview with Aditya Khemka FM... https://t.co/vOHvrYCUQ4 via @YouTube
More from Uvlearnings
https://t.co/hItmOud8Pm
#Hikal has stepped up R&D in recent years. Next few years (capex & launches) should yield superior earnings. Wish them all the luck \U0001f44d
— Sajal Kapoor (@unseenvalue) September 26, 2020
D: invested and biased view for sure, but it was below 1x price to sales vs 12x price to sales for many chemicals and generic players. No reco!! pic.twitter.com/aqPUKbziHK
In an example of how deeply ingrained misogyny is in the Indian system, billionaire investor Rakesh Jhunjhunwala asked the management of Jubilant Pharmova: \u201cHow can we be lower than the lady? We have to beat her,\u201d in a slighting reference to @kiranshaw.
— Dr. Kailashnath Koppikar (@koppik) June 26, 2021
https://t.co/1dkZ9JMLLr
You May Also Like
Those who exited at 1500 needed money. They can always come back near 969. Those who exited at 230 also needed money. They can come back near 95.
Those who sold L @ 660 can always come back at 360. Those who sold S last week can be back @ 301
Sir, Log yahan.. 13 days patience nhi rakh sakte aur aap 2013 ki baat kar rahe ho. Even Aap Ready made portfolio banakar bhi de do to bhi wo 1 month me hi EXIT kar denge \U0001f602
— BhavinKhengarSuratGujarat (@IntradayWithBRK) September 19, 2021
Neuland 2700 se 1500 & Sequent 330 to 230 kya huwa.. 99% retailers/investors twitter par charcha n EXIT\U0001f602